PARIS--(BUSINESS WIRE)--Regulatory News: Cellectis (Paris:ALCLS) (Alternext: ALCLS), the genome engineering specialist, announced that, by the turn of the year, the US Patent and Trademark Office (USPTO) and the Courts of Appeal for the Federal Circuit (CAFC) independently recognized the merits of Cellectis and Institut Pasteur’s early inventions on meganucleases.
Help employers find you! Check out all the jobs and post your resume.
